Stool test could shorten h. pylori treatment to just 7 days

NCT ID NCT07405697

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 7-day course of antibiotics chosen by a stool test works as well as a 14-day course for people with stubborn H. pylori infections. About 290 adults who have failed previous treatment will get a stool test to find which drugs their infection resists, then be randomly assigned to 7 or 14 days of tailored therapy. The goal is to see if the shorter treatment is just as effective, safer, and cheaper.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of antibiotics and acid-reducing drugs chosen based on a stool test
What this could lead to
If successful, this could make H. pylori rescue treatment shorter, cheaper, and more effective by using a simple stool test to guide drug choice.
What could go wrong
This is a Phase 4 trial, but it's not yet recruiting. The shorter 7-day course might not work as well as 14 days, and the stool test may not be widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Renji Hospital, School of Medicine, Shanghai Jiaotong University

    Shanghai, Shanghai Municipality, 200000, China

  • Shanghai Jiangong Hospitail.

    Shanghai, Shanghai Municipality, China

  • Shanghai Tenth People Hospital

    Shanghai, Shanghai Municipality, China

  • Zhongshan Hospital, Fudan University

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.